ICCC Q3 2022 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena

ICCCImmuCell Corporation

$60M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M-6.9% YoY

Gross Profit

$2M38.5% margin

Operating Income

-$616,790-12.9% margin

Net Income

-$655,078-13.7% margin

EPS (Diluted)

$-0.08

QoQ Revenue Growth

+24.2%

Cash Flow

Operating Cash Flow

-$1M

Free Cash Flow

-$2M

Stock-Based Comp.

$85,122

Balance Sheet

Total Assets

$46M

Total Liabilities

$14M

Stockholders' Equity

$32M

Cash & Equivalents

$9M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$5M	-6.9%
Gross Profit	$2M	$2M	-23.7%
Operating Income	-$616,790	$271,090	-327.5%
Net Income	-$655,078	$147,764	-543.3%